Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Dr Sands says Lagoon’s second-line control arm had median overall survival above 10 months, which was surprising. Lurbinectedin’s initial FDA approval rested on a single-arm study with 9.3-month median survival, so today’s second-line comparator sets a higher bar than the old benchmark for relapsed disease.

Related Insights

The control arms (chemotherapy alone) in two major, independent trials, Mariposa 2 and Harmony, both yielded an identical median progression-free survival of 4.4 months. This consistency across studies validates the data and strengthens the conclusion that chemotherapy alone is a poor benchmark post-TKI failure.

Dr Sands says no one expects durvalumab to work differently from atezolizumab when paired with lurbinectedin. Even a positive durvalumab trial that merely matches atezolizumab data would still not answer the larger question of whether lurbinectedin belongs in first-line maintenance for extensive-stage SCLC at all.

Lurbinectedin's effectiveness in second-line SCLC is highly dependent on the chemotherapy-free interval after first-line treatment. Patients with a longer interval (>90 days) show significantly better response rates and disease control, reinforcing that "platinum sensitivity" acts as a proxy for broader cytotoxic drug sensitivity.

While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."

The MFORTE trial revealed a significantly higher rate of brain-only progression in the lurbinectedin arm (27% vs 10%). This pattern suggests the drug's effective systemic control and lack of CNS penetration combine to unmask the brain as a primary sanctuary site for relapse over time.

Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.

Tarlatumab represents a landmark achievement in a field with many failures. It is the only drug for second-line small cell lung cancer (SCLC) to ever demonstrate superiority over a therapeutic control arm (chemotherapy) in a randomized trial, improving survival, toxicity, and symptoms.

An expert emphasizes the historic importance of the Delphi 304 trial, noting it is the only randomized study in second-line SCLC to ever demonstrate a clear survival benefit against an active chemotherapy control arm. The drug showed superiority across all major endpoints, setting a definitive new standard of care.

Early data for Tarlatamab in SCLC maintenance reveals an 82% 12-month overall survival. This is an absolute 30% improvement over the experimental arm of the recent MFORTE trial, signaling a potential paradigm shift in treatment outcomes that far surpasses current immunotherapy combinations.

In the MFORTE trial, the survival curves for the lurbinectedin-atezolizumab arm eventually converge with the atezolizumab-only arm. This indicates the combination provides an additive benefit (delaying progression) rather than true synergy, which would have created a more durable, long-term survival advantage.